Assessment of alternative treatment strategies for chronic genotype 1 hepatitis C

There is great potential to improve health outcomes for Veterans and other patients with chronic genotype 1 (GT1) Hepatitis C (HCV) infections through the use of newly-available triple combination therapies that include directly acting antivirals (DAA) along with recently developed patient genotypin...

Full description

Main Authors: Goldhaber-Fiebert, Jeremy D., Barnett, Paul G. (Author)
Corporate Authors: West Los Angeles VA Medical Center Evidence-Based Synthesis Program Center, VA Health Economics Resource Center (U.S.), Quality Enhancement Research Initiative (U.S.)
Format: eBook
Language:English
Published: Washington, DC Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service [2013], 2013
Series:Evidence-based synthesis program
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:There is great potential to improve health outcomes for Veterans and other patients with chronic genotype 1 (GT1) Hepatitis C (HCV) infections through the use of newly-available triple combination therapies that include directly acting antivirals (DAA) along with recently developed patient genotyping (IL-28B) which is predictive of HCV treatment response. Chronic GT1 HCV infections have been historically difficult to treat, with low cure rates on standard two drug therapy (Pegylated Interferon + Ribavirin), high rates of side-effects and treatment discontinuation, and low rates of uptake. Recently, FDA approved two DAAs (boceprevir and telaprevir). Used in combination with standard two drug therapy as triple therapy, these DAAs show higher rates of sustained viral response, though they are also more costly and have more severe side-effect profiles. IL-28B genotyping can help to identify patients least likely to respond to standard therapy and hence who stand to benefit the most from triple therapy and for whom, therefore, the increased risks of side-effects may be most justified
Item Description:Title from PDF t.p. - "March 2013."
Physical Description:1 PDF file (iii, 37 pages) illustrations